{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:42:54Z","timestamp":1781890974887,"version":"3.54.5"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Multidrug-resistant\n                      <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                      (MDRPA) is a life-threatening infection with limited treatment options. As a novel combination drug of cephalosporin and beta-lactamase inhibitor, ceftazidime\/avibactam (CAZ\/AVI) is not much used in clinical treatment of MDRPA infections. To fill in this knowledge gap, a single-center real-world study was conducted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective observational study included MDRPA-infected patients treated with CAZ\/AVI or other antimicrobial agents between January 2019 and April 2021. Propensity score-matched and binary logistic regression analysis was used to compare the clinical and microbiological efficacy between CAZ\/AVI and other antimicrobial agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Totally 363 patients with MDRPA infection were enrolled, including 49 patients treated with CAZ\/AVI and 314 patients treated with other antimicrobial agents. The CAZ\/AVI group exhibited a reduced failure rate of clinical treatment (P = 0.012, OR = 0.381, 95% CI 0.180 - 0.807). Subgroup analysis showed single lung infection was a significant risk factor for clinical treatment failure in patients treated with other antimicrobial agents (P = 0.023, OR = 2.568, 95% CI 1.138 - 5.796). No significant discrepancy was observed in microbiological efficacy between the two groups (P = 0.159, OR = 0.587, 95% CI 0.280 - 1.232), or in clinical and microbiological efficacy between CAZ\/AVI monotherapy and combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CAZ\/AVI demonstrates superior clinical efficacy against MDRPA in comparison to other antimicrobial agents. However, the administration of CAZ\/AVI as part of combination therapy does not provide any clear benefits over monotherapy. Patients with single pulmonary infection caused by MDRPA show better clinical efficacy with CAZ\/AVI. Further larger studies are needed to substantiate our findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2025.1644991","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:37:52Z","timestamp":1765435072000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of ceftazidime\/avibactam versus other antimicrobial agents for treating multidrug- resistant Pseudomonas aeruginosa: a propensity-matched retrospective analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Qian","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaChen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinYu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChuWei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShuMei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenKui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12866-024-03321-5","article-title":"Characterization and genetic analysis of extensively drug-resistant hospital acquired Pseudomonas aeruginosa isolates","volume":"24","author":"Abdelaziz","year":"2024","journal-title":"BMC Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/IDR.S349004","article-title":"Ceftazidime-avibactam versus colistin for the treatment of infections due to carbapenem-resistant Enterobacterales: a multicenter cohort study","volume":"15","author":"Almangour","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"B3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","article-title":"Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors","volume":"17","author":"Bush","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jac\/dkac049","article-title":"Impact of ceftazidime\/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)","volume":"77","author":"Cast\u00f3n","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0069821","DOI":"10.1128\/AAC.00698-21","article-title":"Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Enterobacterales","volume":"65","author":"Chen","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2147\/IDR.S350976","article-title":"Ceftazidime\/avibactam versus polymyxin B in the challenge of carbapenem-resistant Pseudomonas aeruginosa infection","volume":"15","author":"Chen","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"B7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.mib.2011.07.026","article-title":"Diazabicyclooctanes (DBOs): a potent new class of non-\u03b2-lactam \u03b2-lactamase inhibitors","volume":"14","author":"Coleman","year":"2011","journal-title":"Curr. Opin. Microbiol."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106517","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa","volume":"59","author":"Corbella","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/AAC.03042-15","article-title":"In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014)","volume":"60","author":"de Jonge","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9070388","article-title":"Ceftazidime-avibactam combination therapy compared to ceftazidime-avibactam monotherapy for the treatment of severe infections due to carbapenem-resistant pathogens: a systematic review and network meta-analysis","volume":"9","author":"Fiore","year":"2020","journal-title":"Antibiotics"},{"key":"B12","first-page":"1453","article-title":"Comparison of semi-quantitative endotracheal aspirates to quantitative non-bronchoscopic bronchoalveolar lavage in diagnosing ventilator-associated pneumonia","volume":"54","author":"Fujitani","year":"2009","journal-title":"Respir. Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jgar.2021.04.022","article-title":"Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: ceftazidime-avibactam against CR-KP infections","volume":"26","author":"Gu","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s15010-024-02371-1","article-title":"Ceftazidime-avibactam versus other antimicrobial agents for treatment of Multidrug-resistant Pseudomonas aeruginosa: a systematic review and meta-analysis","volume":"52","author":"Gupta","year":"2024","journal-title":"Infection"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00031","DOI":"10.1128\/CMR.00031-19","article-title":"Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections","volume":"32","author":"Horcajada","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1089\/sur.2024.137","article-title":"The surgical infection society guidelines on the management of intra-abdominal infection: 2024 update","volume":"25","author":"Huston","year":"2024","journal-title":"Surg. Infect. (Larchmt)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2023.106090","article-title":"Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis","volume":"179","author":"Karampatakis","year":"2023","journal-title":"Microb. Pathog."},{"key":"B18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","article-title":"European association of urology guidelines on urological infections: summary of the 2024 guidelines","volume":"86","author":"Kranz","year":"2024","journal-title":"Eur. Urol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.gpb.2022.02.005","article-title":"Genomic epidemiology of carbapenemase-producing Klebsiella pneumoniae in China","volume":"20","author":"Li","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13054-015-0926-5","article-title":"An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance","volume":"19","author":"Micek","year":"2015","journal-title":"Crit. Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciy381","article-title":"A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology","volume":"67","author":"Miller","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9040196","article-title":"Trends, epidemiology, and management of multi-drug resistant Gram-negative bacterial infections in the hospitalized setting","volume":"9","author":"Morris","year":"2020","journal-title":"Antibiotics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-018-0370-9","article-title":"Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis","volume":"7","author":"Raman","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e01045","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob","volume":"61","author":"Sader","year":"2017","journal-title":"Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7860\/JCDR\/2013\/4564.2733","article-title":"Comparative evaluation of the in-vitro activity of six \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Gram negative bacilli","volume":"7","author":"Sood","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1093\/jac\/dky204","article-title":"Clinical activity of ceftazidime\/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime\/avibactam Phase III clinical trial programme","volume":"73","author":"Stone","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1128\/AAC.01282-16","article-title":"Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant \u03b2-lactam resistance mechanisms","volume":"60","author":"Torrens","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/jcpt.13638","article-title":"Observation of clinical efficacy of the cefoperazone\/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection","volume":"47","author":"Wang","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3760\/cma.j.cn112138-20191104-00728","article-title":"The impact of carbapenem-resistance Pseudomonas aeruginosa infections on mortality of patients with hematological disorders","volume":"59","author":"Wei","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B36","unstructured":"WHO bacterial priority pathogens list, 2024\n          \n          2024"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1137811","article-title":"Risk factors and outcomes of inpatients with carbapenem-resistant Pseudomonas aeruginosa bloodstream infections in China: a 9-year trend and multicenter cohort study","volume":"14","author":"Yuan","year":"2023","journal-title":"Front. Microbiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-avibactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1038\/emi.2016.22","article-title":"Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies","volume":"5","author":"Zhang","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3201\/eid2910.230509","article-title":"Pseudomonas aeruginosa high-risk sequence type 463 co-producing KPC-2 and AFM-1 carbapenemases, China, 2020-2022","volume":"29","author":"Zhang","year":"2023","journal-title":"Emerg. Infect. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40121-021-00479-7","article-title":"Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study","volume":"10","author":"Zheng","year":"2021","journal-title":"Infect. Dis. Ther."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1644991\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:37:55Z","timestamp":1765435075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1644991\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":41,"alternative-id":["10.3389\/fcimb.2025.1644991"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1644991","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"article-number":"1644991"}}